These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 25103018

  • 1. Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer.
    Zhao FL, Dou YC, Wang XF, Han DC, Lv ZG, Ge SL, Zhang YK.
    Mol Biol Rep; 2014 Sep; 41(9):5913-22. PubMed ID: 25103018
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.
    Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, Ditzel HJ.
    Mol Oncol; 2014 Jul; 8(5):874-83. PubMed ID: 24694649
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The association of five preoperative serum tumor markers and pathological features in patients with breast cancer.
    Lian M, Zhang C, Zhang D, Chen P, Yang H, Yang Y, Chen S, Hong G.
    J Clin Lab Anal; 2019 Jun; 33(5):e22875. PubMed ID: 30843272
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serum miRNA-1 may serve as a promising noninvasive biomarker for predicting treatment response in breast cancer patients receiving neoadjuvant chemotherapy.
    Peng J, Lin Y, Sheng X, Yuan C, Wang Y, Yin W, Zhou L, Lu J.
    BMC Cancer; 2024 Jul 02; 24(1):789. PubMed ID: 38956544
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Serum microRNA-135a-5p as an auxiliary diagnostic biomarker for colorectal cancer.
    Wang Q, Zhang H, Shen X, Ju S.
    Ann Clin Biochem; 2017 Jan 02; 54(1):76-85. PubMed ID: 27126269
    [Abstract] [Full Text] [Related]

  • 15. Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer.
    Li J, Song ZJ, Wang YY, Yin Y, Liu Y, Nan X.
    Genet Mol Res; 2016 Aug 26; 15(3):. PubMed ID: 27706621
    [Abstract] [Full Text] [Related]

  • 16. Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Gu X, Xue JQ, Han SJ, Qian SY, Zhang WH.
    Cancer Biomark; 2016 Aug 26; 16(3):395-403. PubMed ID: 27062696
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Increased expression of miR-330-3p: a novel independent indicator of poor prognosis in human breast cancer.
    Wang H, Chen SH, Kong P, Zhang LY, Zhang LL, Zhang NQ, Gu H.
    Eur Rev Med Pharmacol Sci; 2018 Mar 26; 22(6):1726-1730. PubMed ID: 29630118
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A Clinical Evaluation of Circulating MiR-106a and Raf-1 as Breast Cancer Diagnostic and Prognostic Markers.
    Ahmed Mohmmed E, Shousha WG, El-Saiid AS, Ramadan SS.
    Asian Pac J Cancer Prev; 2021 Nov 01; 22(11):3513-3520. PubMed ID: 34837907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.